Lifecore Biomedical, Inc. LFCR Gain (loss) on mark-to-market of Escrowed Shares
Gain (loss) on mark-to-market of Escrowed Shares at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnDerivatives.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s gain (loss) on mark-to-market of escrowed shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s gain (loss) on mark-to-market of escrowed shares?
- Lifecore Biomedical, Inc. (LFCR) reported gain (loss) on mark-to-market of escrowed shares of -$3.16M in Q1 2026.
- What does gain (loss) on mark-to-market of escrowed shares mean?
- Reflects the non-cash change in the fair value of derivative financial instruments or escrowed equity arrangements held by the company. These gains or losses are recognized in the income statement due to market fluctuations but do not involve immediate cash inflows or outflows. Investors track this to isolate core operational performance from volatility driven by financial market instruments.